UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 96

Sortiert nach

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

Annals of oncology, 2019-06, Vol.30 (6), p.921-926

2019

Volltextzugriff (PDF)

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival

ESMO open, 2022-04, Vol.7 (2), p.100409-100409, Article 100409

2022

Volltextzugriff (PDF)

A systematic review of contemporary phase I trials in patients with lymphoma

Critical reviews in oncology/hematology, 2022-12, Vol.180, p.103860-103860, Article 103860

2022

Volltextzugriff (PDF)

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Breast cancer research and treatment, 2017-06, Vol.163 (2), p.295-302

2017

Volltextzugriff (PDF)

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

ESMO open, 2022-04, Vol.7 (2), p.100433, Article 100433

2022

Volltextzugriff (PDF)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

NPJ precision oncology, 2021-03, Vol.5 (1), p.23-23, Article 23

2021

Volltextzugriff (PDF)

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab

British journal of cancer, 2014-07, Vol.111 (1), p.25-32

2014

Volltextzugriff (PDF)

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

Investigational new drugs, 2017-12, Vol.35 (6), p.766-772

2017

Volltextzugriff (PDF)

ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

Annals of oncology, 2019-05, Vol.30, p.iii7-iii7

2019

Volltextzugriff (PDF)

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]

ESMO open, 2022-06, Vol.7 (3), p.100472-100472, Article 100472

2022

Volltextzugriff (PDF)

Fat grafting for breast cancer patients: From basic science to clinical studies

European journal of surgical oncology, 2016-08, Vol.42 (8), p.1088-1102

2016

Volltextzugriff (PDF)

Oncological outcome of fat grafting for breast reconstruction after cancer

Annals of oncology, 2018-10, Vol.29, p.viii81-viii81

2018

Volltextzugriff (PDF)

A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)

Annals of oncology, 2018-10, Vol.29, p.viii63-viii63

2018

Volltextzugriff (PDF)

Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi39

2017

Volltextzugriff (PDF)

First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi31

2017

Volltextzugriff (PDF)

Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Breast cancer research and treatment, 2017-06, Vol.163 (3), p.637-637

2017

Volltextzugriff (PDF)

Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors

European journal of cancer (1990), 2017-02, Vol.72, p.S134-S134

2017

Volltextzugriff (PDF)

A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi27

2017

Volltextzugriff (PDF)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

ESMO open, 2021-04, Vol.6 (2), p.100099-100099, Article 100099

2021

Volltextzugriff (PDF)

316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors

European journal of cancer (1990), 2015-09, Vol.51, p.S60-S60

2015

Volltextzugriff (PDF)

335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors

European journal of cancer (1990), 2015-09, Vol.51, p.S66-S66

2015

Volltextzugriff (PDF)

Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients

European journal of cancer (1990), 2022-11, Vol.175, p.S57-S58

2022

Volltextzugriff (PDF)

117O Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials

Annals of oncology, 2021-09, Vol.32, p.S407-S407

2021

Volltextzugriff (PDF)

Temporal evolution of breast cancer brain metastases treatments and outcomes

European journal of cancer (1990), 2024-03, Vol.200, p.113707, Article 113707

2024

Volltextzugriff (PDF)

26P Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin

Annals of oncology, 2022-05, Vol.33, p.S135-S136

2022

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(96)

Sprache

Englisch
(96)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Oncology
(14)
Life Sciences & Biomedicine
(13)
Female
(10)
Humans
(10)
Breast Cancer
(9)
Breast Neoplasms - Drug Therapy
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Chemotherapy
(6)
Trastuzumab
(6)
Biomarkers
(5)
Tumors
(5)
Aged
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Breast Neoplasms - Pathology
(4)
Clinical Trials
(4)
Hematology, Oncology And Palliative Medicine
(4)
Middle Aged
(4)
Physical Sciences
(4)
Physics
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival

A systematic review of contemporary phase I trials in patients with lymphoma

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]

Fat grafting for breast cancer patients: From basic science to clinical studies

Oncological outcome of fat grafting for breast reconstruction after cancer

A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)

Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study

First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients

Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors

A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors

335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors

Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients

117O Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials

Temporal evolution of breast cancer brain metastases treatments and outcomes

26P Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin

Suchergebnisse filtern